You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

osimertinib

Showing 1 - 25 of 113
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in

Not yet recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +2 more
  • Cetuximab
  • +2 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Oct 2, 2023

NSCLC With Mutation in Epidermal Growth Factor Receptor Trial (Osimertinib, Aspirin)

Not yet recruiting
  • Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
  • (no location specified)
Aug 27, 2023

NSCLC Trial in Santa Rosa, Ridgewood (Tipifarnib, Osimertinib)

Recruiting
  • NSCLC
  • Santa Rosa, California
  • +1 more
Jan 11, 2023

NSCLC, Stage I Trial in Tianjin (Osimertinib)

Recruiting
  • NSCLC, Stage I
  • Osimertinib
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute & Hospital
Jan 6, 2023

Colorectal Cancer, NSCLC Trial (GDC-1971, Osimertinib, Cetuximab)

Not yet recruiting
  • Colorectal Cancer
  • Non-Small Cell Lung Cancer
  • (no location specified)
Jul 12, 2023

NSCLC Trial in China (BBP-398, osimertinib)

Recruiting
  • NSCLC
  • Beijing, Beijing, China
  • +4 more
Sep 4, 2023

Cancer Trial (Osimertinib)

Not yet recruiting
  • Cancer
  • Osimertinib
  • (no location specified)
Nov 17, 2022

NSCLC (NSCLC) Trial (Osimertinib, Amivantamab)

Not yet recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • (no location specified)
Mar 24, 2023

NSCLC Trial (Telisotuzumab Vedotin, Osimertinib, Cisplatin)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Telisotuzumab Vedotin
  • +4 more
  • (no location specified)
Oct 17, 2023

Lung Adenocarcinoma, Lung Tumors Trial run by the NCI (osimertinib, LAT)

Completed
  • Lung Adenocarcinoma
  • Lung Neoplasms
  • osimertinib
  • LAT
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Oct 17, 2022

Non Small Cell Lung Cancer, Lung Cancer Trial in Los Angeles (Osimertinib, Carotuximab)

Recruiting
  • Non Small Cell Lung Cancer
  • Lung Cancer
  • Los Angeles, California
    Cedars-Sinai Medical Center
Dec 20, 2022

Lung Cancer Metastatic, EGFR Gene Mutation Trial in San Francisco (Osimertinib, Alisertib)

Recruiting
  • Lung Cancer Metastatic
  • EGFR Gene Mutation
  • San Francisco, California
    University of California, San Francisco
Aug 10, 2022

Non Small Cell Lung Cancer Trial in Italy (Osimertinib)

Recruiting
  • Non Small Cell Lung Cancer
  • Osimertinib
  • Ancona, Italy
  • +10 more
Mar 14, 2023

NSCLC Trial in Boston (Osimertinib)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Osimertinib
  • Boston, Massachusetts
  • +1 more
Sep 28, 2022

Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8 Trial in Houston

Active, not recruiting
  • Recurrent Lung Non-Small Cell Carcinoma
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 31, 2022

NSCLC (NSCLC) Trial in Japan, United States (Patritumab deruxtecan, Osimertinib)

Recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • Patritumab deruxtecan
  • Osimertinib
  • Santa Monica, California
  • +13 more
Feb 1, 2023

Non Small Cell Lung Cancer Trial in Beijing (Osimertinib, Pemetrexed/Carboplatin)

Recruiting
  • Non Small Cell Lung Cancer
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Mar 3, 2022

NSCLC, EGFR Activating Mutation Trial in Changsha, Shanghai (TY-9591, Osimertinib, Osimertinib)

Recruiting
  • NSCLC
  • EGFR Activating Mutation
  • Changsha, Hunan, China
  • +1 more
Dec 6, 2022

Osimertinib for NSCLC With Uncommon EGFR Mutations

Enrolling by invitation
  • Carcinoma, Non-Small-Cell Lung
  • Genes, erbB-1
  • Osimertinib
  • Ramat Gan, Israel
    Sheba Medical Centre
Jun 14, 2022

NSCLC, EGFR Positive NSCLC, Oligoprogression Trial in München (Osimertinib, Radiotherapy)

Recruiting
  • NSCLC
  • +2 more
  • Osimertinib
  • Radiotherapy
  • München, Germany
    LMU Klinikum der Universität München
May 17, 2022

EGFR T790M, Osimertinib, NSCLC Trial in Beijing (Osimertinib)

Recruiting
  • EGFR T790M
  • +3 more
  • Osimertinib
  • Beijing, Beijing, China
    Junling Li
Jul 21, 2022

NSCLC, NSCLC Trial in Miami, Cleveland (Osimertinib)

Active, not recruiting
  • NSCLC
  • Non-small Cell Lung Cancer
  • Osimertinib
  • Miami, Florida
  • +1 more
Nov 8, 2022

NSCLC Trial in China (Osimertinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Osimertinib
  • Beijing, China
  • +3 more
Sep 15, 2022

NSCLC Trial in Netherlands (Trastuzumab emtansine, Osimertinib)

Terminated
  • Carcinoma, Non-Small-Cell Lung
  • Trastuzumab emtansine
  • Osimertinib
  • Maastricht, Limburg, Netherlands
  • +4 more
Nov 7, 2022

Non Small Cell Lung Cancer Trial in Tianjin (Osimertinib, Bevacizumab Biosimilar IBI305, Carboplatin)

Recruiting
  • Non Small Cell Lung Cancer
  • Osimertinib
  • +3 more
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Aug 18, 2022